Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

AGEN

Agenus Inc

Last Close
Jul 26 • 04:00PM ET
6.56
Dollar change
+0.59
Percentage change
9.97 		%
Held by: VTI VXF IWM DWAS VTWO VHT IWN SCHA IWC FESM
IndexRUT P/E- EPS (ttm)-12.62 Insider Own5.03% Shs Outstand21.00M Perf Week9.52%
Market Cap137.76M Forward P/E- EPS next Y-9.57 Insider Trans89.88% Shs Float19.94M Perf Month-53.84%
Income-239.61M PEG- EPS next Q-1.07 Inst Own52.01% Short Float12.01% Perf Quarter-20.96%
Sales161.42M P/S0.85 EPS this Y25.84% Inst Trans- Short Ratio2.57 Perf Half Y-45.32%
Book/sh-9.59 P/B- EPS next Y6.49% ROA-71.52% Short Interest2.39M Perf Year-78.13%
Cash/sh2.52 P/C2.61 EPS next 5Y- ROE- 52W Range4.78 - 32.00 Perf YTD-60.38%
Dividend Est.- P/FCF- EPS past 5Y13.79% ROI- 52W High-79.50% Beta1.40
Dividend TTM- Quick Ratio0.24 Sales past 5Y98.93% Gross Margin90.51% 52W Low37.38% ATR (14)1.70
Dividend Ex-Date- Current Ratio0.24 EPS Y/Y TTM22.36% Oper. Margin-85.64% RSI (14)31.11 Volatility13.39% 12.71%
Employees389 Debt/Eq- Sales Y/Y TTM69.94% Profit Margin-148.44% Recom2.60 Target Price19.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q29.41% Payout- Rel Volume0.81 Prev Close5.97
Sales Surprise-40.63% EPS Surprise5.20% Sales Q/Q22.28% EarningsAug 08 BMO Avg Volume932.70K Price6.56
SMA20-49.36% SMA50-52.46% SMA200-52.08% Trades Volume758,943 Change9.97%
Date Action Analyst Rating Change Price Target Change
Jul-19-24Downgrade Robert W. Baird Outperform → Neutral $35 → $8
Jul-18-24Downgrade William Blair Outperform → Mkt Perform
Jul-18-24Downgrade H.C. Wainwright Buy → Neutral $9
Jun-06-23Initiated Robert W. Baird Outperform $8
Jun-06-23Initiated Robert W. Baird Outperform $60 → $80
Feb-28-23Resumed H.C. Wainwright Buy $8
Sep-28-22Initiated SMBC Nikko Outperform $5
Dec-16-21Initiated H.C. Wainwright Buy $12
Nov-19-19Resumed B. Riley FBR Buy $6
Apr-22-19Initiated B. Riley FBR Buy
Show Previous Ratings
Today 07:00AM
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
(Business Wire) +9.97%
Jul-19-24 10:39AM
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
(Zacks) -17.95%
07:47AM
Lilly alone in bidding for Morphic; Novartis wont yet file MorphoSys drug
(BioPharma Dive)
Jul-18-24 07:00AM
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
(Business Wire) -58.83%
Jun-28-24 11:10AM
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
(Business Wire) +18.63%
07:30AM Loading…
Jun-27-24 07:30AM
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
(Business Wire)
Jun-17-24 07:00AM
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
(Business Wire) -7.50%
Jun-13-24 05:15AM
Nature Medicine Reports Agenus Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
(Business Wire) -5.44%
Jun-04-24 07:30AM
Agenus Announces Virtual Annual Shareholders Meeting
(Business Wire)
May-30-24 03:30PM
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
(InvestorPlace)
May-27-24 12:32PM
7 Biotech Stocks to Put on Your Breakthrough Radar
(InvestorPlace)
May-24-24 05:00PM
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) +10.28% +11.97%
May-23-24 05:10PM
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
(Business Wire)
07:30AM
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
(Business Wire)
May-22-24 07:30AM
3 Magnificent Growth Stocks to Buy Hand Over Fist
(Motley Fool) +7.10%
07:30AM Loading…
May-16-24 07:30AM
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
(Business Wire)
May-08-24 01:22PM
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript
(Insider Monkey)
11:11AM
Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript
(Insider Monkey)
03:09AM
Agenus Inc (AGEN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
(GuruFocus.com)
May-07-24 05:45PM
Agenus (AGEN) Q1 2024 Earnings Call Transcript
(Motley Fool) -7.26%
01:52PM
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading
(MT Newswires)
12:24PM
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates
(MT Newswires)
09:00AM
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
08:56AM
Agenus Inc (AGEN) Q1 2024 Earnings: Misses Revenue and EPS Estimates Amid Strategic Developments
(GuruFocus.com)
07:59AM
Agenus: Q1 Earnings Snapshot
(Associated Press Finance)
07:40AM
Agenus Reports First Quarter 2024 Results
(Business Wire)
07:30AM
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
(Business Wire)
May-01-24 07:30AM
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
(Business Wire) +9.41%
Apr-28-24 08:30AM
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
(Motley Fool)
Apr-24-24 10:00AM
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
(Business Wire) +14.86%
07:30AM Loading…
Apr-23-24 07:30AM
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
(Business Wire) +11.96%
Apr-22-24 04:17AM
Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
(Zacks) +8.66%
Apr-12-24 07:30AM
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
(Business Wire) -8.12%
Apr-08-24 03:34AM
Down 75%. Is Agenus Stock a Buy on the Dip?
(Motley Fool) -7.58%
Apr-05-24 04:30PM
Agenus Announces Reverse Stock Split of Common Stock
(Business Wire)
Apr-03-24 04:19AM
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
(Motley Fool)
Mar-24-24 04:05PM
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
(InvestorPlace)
Mar-22-24 01:25PM
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Mar-15-24 02:11PM
Agenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript
(Insider Monkey) -9.95%
Mar-14-24 01:30PM
Agenus (AGEN) Q4 2023 Earnings Call Transcript
(Motley Fool) -8.94%
08:51AM
Agenus Inc (AGEN) Reports Full Year and Q4 2023 Financial Results, Advances in Oncology Pipeline
(GuruFocus.com)
07:39AM
Agenus: Q4 Earnings Snapshot
(Associated Press Finance)
07:30AM
Agenus Reports Fourth Quarter and Full Year 2023 Results
(Business Wire)
Mar-06-24 07:30AM
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
(Business Wire)
Mar-05-24 04:30PM
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Feb-29-24 07:30AM
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
(Business Wire) -10.81%
Feb-26-24 07:30AM
Agenus to Participate in Leerink Partners Global Biopharma Conference
(Business Wire) +6.36%
Feb-15-24 06:38PM
Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today
(Motley Fool) -29.54%
07:02AM
Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design
(PR Newswire)
Feb-01-24 07:09PM
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
(InvestorPlace)
Jan-31-24 07:30AM
Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
(Business Wire) +5.32%
Jan-26-24 03:57PM
3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024
(InvestorPlace) +10.47%
Jan-22-24 07:30AM
Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population
(Business Wire)
Jan-05-24 04:30PM
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jan-04-24 07:30AM
Agenus to Participate in B. Riley Healthcare Conference
(Business Wire)
Dec-24-23 09:45AM
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
(Motley Fool)
Dec-20-23 07:30AM
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
(Business Wire)
Dec-11-23 07:30AM
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
(Business Wire) -8.91%
Nov-07-23 06:55AM
Agenus Inc (AGEN) Reports Q3 2023 Results: Revenue of $24.3 Million and Net Loss of $64.5 Million
(GuruFocus.com)
06:41AM
Agenus: Q3 Earnings Snapshot
(Associated Press Finance)
06:30AM
Agenus Reports Third Quarter 2023 Results
(Business Wire)
Oct-26-23 09:05AM
Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
(Business Wire)
Oct-22-23 12:00PM
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
(Business Wire)
Oct-21-23 04:15AM
ESMO 2023: Agenus Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
(Business Wire)
Oct-10-23 07:30AM
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer
(Business Wire) +5.94%
Oct-05-23 07:30AM
Agenus To Host BOT/BAL Program Update at ESMO 2023
(Business Wire)
Sep-01-23 04:30PM
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) -7.91%
Aug-28-23 08:30AM
3 Magnificent Growth Stocks to Buy on the Dip
(Motley Fool) +5.34%
07:30AM
Agenus to Participate in September Investor Conferences
(Business Wire)
Aug-24-23 09:54AM
Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7%
(Zacks) -5.00%
Aug-23-23 02:00PM
Watertown biotech shares spike after accidental data publication at Roche
(American City Business Journals) -7.28%
01:16PM
Lexington biotech lays off 91 as it narrows focus
(American City Business Journals)
08:00AM
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
(Business Wire)
Aug-18-23 04:27AM
Q2 2023 Xilio Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) +11.36%
Aug-17-23 10:04AM
Billionaire Steve Cohen Loads Up on These 2 Strong Buy Penny Stocks Heres Why Wall Street Sees Over 500% Upside Potential
(TipRanks)
Aug-09-23 08:30AM
SaponiQx Announces Breakthrough in Scaling Up of STIMULON Cultured Plant Cell Adjuvant
(Business Wire)
Aug-08-23 10:00AM
Compared to Estimates, Agenus (AGEN) Q2 Earnings: A Look at Key Metrics
(Zacks) -8.09%
08:19AM
Agenus: Q2 Earnings Snapshot
(AP Finance)
07:30AM
Agenus Reports Second Quarter 2023 Results
(Business Wire)
Aug-03-23 05:25PM
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
(Zacks)
Jul-28-23 07:30AM
Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
(Business Wire) +5.52%
Jul-26-23 07:30AM
Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update
(Business Wire)
Jul-20-23 07:30AM
Agenus Expands Executive Leadership Team
(Business Wire)
Jul-10-23 07:58AM
With 52% institutional ownership, Agenus Inc. (NASDAQ:AGEN) is a favorite amongst the big guns
(Simply Wall St.) +10.98%
Jun-30-23 11:15AM
ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer
(Business Wire)
Jun-26-23 10:15AM
2 Low-Priced Stocks That Could Make You Richer
(Motley Fool) -5.20%
Jun-06-23 07:46AM
Even after rising 19% this past week, Agenus (NASDAQ:AGEN) shareholders are still down 53% over the past three years
(Simply Wall St.) +6.94%
Jun-05-23 09:49AM
Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO
(Business Wire) +8.12%
07:30AM
Agenus Announces Virtual Annual Shareholders Meeting
(Business Wire)
May-25-23 07:30AM
Agenus to Participate in Jefferies Healthcare Conference
(Business Wire)
May-10-23 06:11AM
Broker Revenue Forecasts For Agenus Inc. (NASDAQ:AGEN) Are Surging Higher
(Simply Wall St.)
May-09-23 07:00PM
Agenus (AGEN) Q1 2023 Earnings Call Transcript
(Motley Fool) -5.66%
09:15AM
Agenus (AGEN) Reports Q1 Loss, Lags Revenue Estimates
(Zacks)
08:10AM
Agenus: Q1 Earnings Snapshot
(AP Finance)
08:00AM
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
(Business Wire)
May-03-23 09:08AM
Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI
(Business Wire) +5.67%
Apr-26-23 10:35AM
Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting
(Business Wire)
Apr-25-23 07:30AM
Agenus to Provide Corporate Update and First Quarter 2023 Financial Report
(Business Wire) -5.75%
Apr-24-23 07:30AM
Agenus to Participate in May Investor Conferences
(Business Wire)
Apr-18-23 11:20AM
Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug
(Zacks)
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARMEN GARO HSee RemarksFeb 15 '24Buy0.65500,000324,050625,969Feb 15 06:59 PM
WIINBERG ULFDirectorNov 15 '23Buy0.7625,00019,000124,063Nov 17 04:22 PM
AGENUS INC10% OwnerOct 16 '23Buy1.1042947221,772,863Oct 16 05:49 PM
AGENUS INC10% OwnerOct 13 '23Buy1.1019,37321,31021,772,434Oct 16 05:49 PM
AGENUS INC10% OwnerOct 12 '23Buy1.103,1733,48821,753,061Oct 16 05:49 PM
AGENUS INC10% OwnerOct 04 '23Buy1.0915,00116,38021,749,888Oct 06 04:26 PM
AGENUS INC10% OwnerAug 29 '23Buy1.5229,67845,01621,734,887Aug 31 05:53 PM
AGENUS INC10% OwnerAug 28 '23Buy1.4512,80818,57021,705,209Aug 28 05:15 PM
AGENUS INC10% OwnerAug 24 '23Buy1.54170,244262,90821,692,401Aug 28 05:15 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

INKT

MiNK Therapeutics Inc

Last Close
Jul 26 • 04:00PM ET
0.8984
Dollar change
-0.0316
Percentage change
-3.40 		%
INKT MiNK Therapeutics Inc daily Stock Chart
Held by: VTI VXF IWC
Index- P/E- EPS (ttm)-0.60 Insider Own84.78% Shs Outstand34.60M Perf Week2.09%
Market Cap31.20M Forward P/E- EPS next Y-0.44 Insider Trans0.00% Shs Float5.28M Perf Month0.94%
Income-20.59M PEG- EPS next Q-0.10 Inst Own2.70% Short Float1.61% Perf Quarter3.12%
Sales0.00M P/S- EPS this Y37.95% Inst Trans27.24% Short Ratio0.53 Perf Half Y4.47%
Book/sh-0.59 P/B- EPS next Y-8.26% ROA-175.32% Short Interest0.08M Perf Year-48.66%
Cash/sh0.17 P/C5.36 EPS next 5Y- ROE-1238.95% 52W Range0.75 - 1.96 Perf YTD-16.04%
Dividend Est.- P/FCF- EPS past 5Y2.37% ROI- 52W High-54.16% Beta0.06
Dividend TTM- Quick Ratio0.54 Sales past 5Y-25.00% Gross Margin- 52W Low19.79% ATR (14)0.10
Dividend Ex-Date- Current Ratio0.54 EPS Y/Y TTM22.20% Oper. Margin0.00% RSI (14)45.06 Volatility8.20% 10.51%
Employees31 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.33 Target Price8.50
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q34.23% Payout- Rel Volume0.31 Prev Close0.93
Sales Surprise- EPS Surprise27.87% Sales Q/Q- EarningsMay 14 BMO Avg Volume159.01K Price0.90
SMA20-5.24% SMA50-6.29% SMA200-8.02% Trades Volume48,951 Change-3.40%
Jul-11-24 12:00PM
MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know
(Zacks) +11.36%
Jun-05-24 07:30AM
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
(GlobeNewswire)
May-22-24 07:30AM
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
(GlobeNewswire)
May-15-24 03:04AM
MiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ...
(GuruFocus.com) -7.14%
May-14-24 11:52AM
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024
(InvestorPlace) +14.31%
07:30AM Loading…
07:30AM
MiNK Reports First Quarter 2024 Results
(GlobeNewswire)
May-13-24 07:30AM
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
(GlobeNewswire) +8.87%
Apr-30-24 07:30AM
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
(GlobeNewswire)
Apr-08-24 12:00PM
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
(GlobeNewswire) -15.38%
Mar-25-24 12:00PM
All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy
(Zacks) +5.47%
Mar-22-24 01:25PM
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Mar-21-24 11:06PM
Q4 2023 Mink Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
11:53AM
INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023
(InvestorPlace)
07:00AM
MiNK Reports Fourth Quarter and Year-End 2023 Results
(GlobeNewswire)
Mar-07-24 07:30AM
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
(GlobeNewswire)
08:30AM Loading…
Mar-06-24 08:30AM
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
(GlobeNewswire)
Feb-14-24 08:00AM
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK's Allogeneic INKT Cell Therapy and Agenus' Botensilimab and Balstilimab
(GlobeNewswire) +7.75%
Feb-06-24 08:00AM
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
(GlobeNewswire) +10.25%
Jan-30-24 08:00AM
MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
(GlobeNewswire)
Dec-20-23 07:30AM
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
(GlobeNewswire)
Nov-09-23 08:05AM
MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challenges
(GuruFocus.com) -6.72%
07:00AM
MiNK Therapeutics Reports Third Quarter 2023 Results
(GlobeNewswire)
Nov-03-23 12:00PM
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
(GlobeNewswire) +13.59%
Oct-30-23 08:00AM
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
(GlobeNewswire) +7.62%
Sep-27-23 09:05AM
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
(GlobeNewswire)
Aug-24-23 08:30AM
MiNK Therapeutics to Participate in September Investor Conferences
(GlobeNewswire) -8.24%
Aug-10-23 07:30AM
MiNK Therapeutics Reports Second Quarter 2023 Results
(GlobeNewswire) +6.67%
Jul-28-23 08:30AM
MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
(GlobeNewswire)
Jun-05-23 07:30AM
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
(GlobeNewswire)
May-22-23 08:30AM
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
(GlobeNewswire) +16.85%
08:30AM Loading…
May-18-23 08:30AM
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
(GlobeNewswire)
May-11-23 08:00AM
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
(GlobeNewswire) +7.28%
Apr-27-23 08:30AM
MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
(GlobeNewswire) -8.29%
Apr-18-23 01:32PM
MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
(GlobeNewswire)
Apr-16-23 08:03AM
We're Keeping An Eye On MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate
(Simply Wall St.)
Apr-04-23 09:55AM
MiNK Therapeutics, Inc. (INKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
(Zacks)
Mar-30-23 08:41AM
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
(Business Wire) -6.38%
Mar-29-23 12:00PM
MiNK Therapeutics, Inc. (INKT) Upgraded to Buy: What Does It Mean for the Stock?
(Zacks)
Mar-24-23 07:36AM
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2022 Earnings Call Transcript
(Insider Monkey)
Mar-21-23 08:00AM
MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
(GlobeNewswire)
Mar-15-23 08:45AM
MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting
(GlobeNewswire) -5.63%
Mar-07-23 09:00AM
MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
(GlobeNewswire) +7.35%
Feb-16-23 09:28AM
MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference
(GlobeNewswire)
Jan-11-23 02:25PM
MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference
(GlobeNewswire)
Dec-22-22 10:49AM
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Call Transcript
(Insider Monkey)
Nov-17-22 09:00AM
MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference
(GlobeNewswire) -5.90%
Nov-10-22 09:05AM
MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline
(GlobeNewswire) -12.80%
Nov-06-22 09:39AM
Will MiNK Therapeutics (NASDAQ:INKT) Spend Its Cash Wisely?
(Simply Wall St.)
Nov-03-22 08:00AM
MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results
(GlobeNewswire) +5.63%
Oct-20-22 09:00AM
MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update
(GlobeNewswire)
Oct-05-22 09:16AM
MiNK Therapeutics to Host R&D Event November 10, 2022
(GlobeNewswire) +6.76%
08:30AM
MiNK Selected for Five Presentations at Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting
(GlobeNewswire)
Aug-31-22 09:00AM
MiNK Therapeutics to Participate at Upcoming Investor Conferences
(GlobeNewswire) +14.35%
Aug-16-22 06:16AM
Do Insiders Own Lots Of Shares In MiNK Therapeutics, Inc. (NASDAQ:INKT)?
(Simply Wall St.)
Aug-09-22 08:00AM
MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results
(GlobeNewswire)
Aug-02-22 08:30AM
MiNK Therapeutics to Participate at BTIG Biotechnology Conference
(GlobeNewswire)
Jul-27-22 08:30AM
MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update
(GlobeNewswire) +6.06%
May-25-22 08:30AM
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
(GlobeNewswire)
May-10-22 08:00AM
MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report
(GlobeNewswire) -13.64%
May-09-22 08:43AM
Here's Why We're Not Too Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Situation
(Simply Wall St.) -9.74%
Apr-27-22 05:19PM
MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update
(GlobeNewswire) +15.25% -12.84%
Mar-18-22 08:30AM
MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
(GlobeNewswire)
Mar-03-22 04:35PM
MiNK Therapeutics to Report Fourth Quarter & Full Year 2021 Financial Results and Business Update
(GlobeNewswire)
09:28AM
MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers
(GlobeNewswire)
Mar-01-22 08:00AM
Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
(GlobeNewswire)
Jan-15-22 07:47AM
Could The MiNK Therapeutics, Inc. (NASDAQ:INKT) Ownership Structure Tell Us Something Useful?
(Simply Wall St.)
Jan-12-22 09:41AM
MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference
(GlobeNewswire) +7.69%
Nov-17-21 04:15PM
MiNK Therapeutics to Participate in 4th Annual Evercore ISI HealthCONx Conference
(GlobeNewswire) +5.01% -5.83%
Nov-12-21 07:30PM
Agenus inc (AGEN) Q3 2021 Earnings Call Transcript
(Motley Fool) -18.12% +6.28%
07:00AM
MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797
(GlobeNewswire)
Nov-09-21 08:00AM
MiNK Therapeutics Presents New Preclinical and Clinical Data on iNKT Cell Therapy Programs at SITC 2021
(GlobeNewswire)
08:00AM
Agenus Corporate Update and Third Quarter 2021 Financial Report
(GlobeNewswire)
Oct-19-21 04:25PM
MiNK Therapeutics Announces Closing of Initial Public Offering
(GlobeNewswire)
Oct-15-21 05:31PM
Paragon 28 Stock Gains in Trading Debut, While MiNK Rebounds
(Barrons.com)
Oct-14-21 08:29PM
MiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering
(GlobeNewswire)
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AGENUS INC10% OwnerOct 16 '23Buy1.1042947221,772,863Oct 16 05:49 PM
AGENUS INC10% OwnerOct 13 '23Buy1.1019,37321,31021,772,434Oct 16 05:49 PM
AGENUS INC10% OwnerOct 12 '23Buy1.103,1733,48821,753,061Oct 16 05:49 PM
AGENUS INC10% OwnerOct 04 '23Buy1.0915,00116,38021,749,888Oct 06 04:26 PM
AGENUS INC10% OwnerAug 29 '23Buy1.5229,67845,01621,734,887Aug 31 05:53 PM
AGENUS INC10% OwnerAug 28 '23Buy1.4512,80818,57021,705,209Aug 28 05:15 PM
AGENUS INC10% OwnerAug 24 '23Buy1.54170,244262,90821,692,401Aug 28 05:15 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.